News
Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
24/7 Wall St. on MSN13h
Hims & Hers (HIMS) Blows Out Earnings ExpectationsHims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims & Hers Health (NYSE:HIMS) stock spikes, risking a short squeeze given its elevated short interest. Read more here.
Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...
Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
Hims & Hers Health on Monday announced Nader Kabbani, a former Amazon executive who helped establish many of its health-care ...
Palantir Technologies raises its full-year outlook but the stock falls, while Ford suspends guidance because of uncertainty ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback